Trial Outcomes & Findings for Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate (NCT NCT03659929)
NCT ID: NCT03659929
Last Updated: 2024-09-03
Results Overview
Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.
COMPLETED
PHASE3
320 participants
Week 5 (Visit 7)
2024-09-03
Participant Flow
Participant milestones
| Measure |
Placebo
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Overall Study
STARTED
|
106
|
107
|
107
|
|
Overall Study
COMPLETED
|
92
|
87
|
87
|
|
Overall Study
NOT COMPLETED
|
14
|
20
|
20
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Baseline characteristics by cohort
| Measure |
Placebo
n=106 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=107 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=107 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Total
n=320 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
34.2 years
STANDARD_DEVIATION 10.75 • n=99 Participants
|
35.6 years
STANDARD_DEVIATION 10.28 • n=107 Participants
|
33.5 years
STANDARD_DEVIATION 9.35 • n=206 Participants
|
34.4 years
STANDARD_DEVIATION 10.15 • n=7 Participants
|
|
Sex: Female, Male
Female
|
52 Participants
n=99 Participants
|
50 Participants
n=107 Participants
|
44 Participants
n=206 Participants
|
146 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
54 Participants
n=99 Participants
|
57 Participants
n=107 Participants
|
63 Participants
n=206 Participants
|
174 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
14 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
41 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
92 Participants
n=99 Participants
|
94 Participants
n=107 Participants
|
93 Participants
n=206 Participants
|
279 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
6 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
9 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
13 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
41 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
80 Participants
n=99 Participants
|
89 Participants
n=107 Participants
|
88 Participants
n=206 Participants
|
257 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
ADHD Type
Inattentive
|
14 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
53 Participants
n=7 Participants
|
|
ADHD Type
Hyperactive/Impulsive
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
ADHD Type
Combined
|
91 Participants
n=99 Participants
|
88 Participants
n=107 Participants
|
87 Participants
n=206 Participants
|
266 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: Week 5 (Visit 7)Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.
Outcome measures
| Measure |
Placebo
n=103 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms
|
-11.1 score on a scale
Standard Error 1.28
|
-18.2 score on a scale
Standard Error 1.28
|
-18.1 score on a scale
Standard Error 1.27
|
SECONDARY outcome
Timeframe: Up to 5 weeksItems are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.
Outcome measures
| Measure |
Placebo
n=103 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
Hyperactivity/Impulsivity Subscale
|
-5.2 score on a scale
Standard Error 0.61
|
-8.3 score on a scale
Standard Error 0.61
|
-8.0 score on a scale
Standard Error 0.6
|
|
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
Inattentive Subscale
|
-5.9 score on a scale
Standard Error 0.74
|
-9.9 score on a scale
Standard Error 0.74
|
-10.0 score on a scale
Standard Error 0.74
|
SECONDARY outcome
Timeframe: Up to 5 weeksCGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Outcome measures
| Measure |
Placebo
n=103 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 3 (Week 1)
|
-0.5 score on a scale
Standard Error 0.1
|
-0.9 score on a scale
Standard Error 0.1
|
-1.0 score on a scale
Standard Error 0.1
|
|
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 4 (Week 2)
|
-0.7 score on a scale
Standard Error 0.12
|
-1.1 score on a scale
Standard Error 0.12
|
-1.3 score on a scale
Standard Error 0.12
|
|
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 5 (Week 3)
|
-0.8 score on a scale
Standard Error 0.12
|
-1.4 score on a scale
Standard Error 0.12
|
-1.5 score on a scale
Standard Error 0.12
|
|
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 6 (Week 4)
|
-0.8 score on a scale
Standard Error .12
|
-1.4 score on a scale
Standard Error .12
|
-1.5 score on a scale
Standard Error 0.12
|
|
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 7 (End of Study/End of Treatment)
|
-0.9 score on a scale
Standard Error .13
|
-1.5 score on a scale
Standard Error .13
|
-1.5 score on a scale
Standard Error .13
|
SECONDARY outcome
Timeframe: Up to 5 weeks"Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."
Outcome measures
| Measure |
Placebo
n=103 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 7 (End of Study/End of Treatment)
|
3.1 score on a scale
Standard Error 0.12
|
2.5 score on a scale
Standard Error 0.12
|
2.4 score on a scale
Standard Error 0.12
|
|
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 3 (Week 1)
|
3.3 score on a scale
Standard Error 0.1
|
2.9 score on a scale
Standard Error 0.1
|
2.8 score on a scale
Standard Error 0.1
|
|
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 4 (Week 2)
|
3.2 score on a scale
Standard Error 0.11
|
2.6 score on a scale
Standard Error 0.11
|
2.4 score on a scale
Standard Error 0.11
|
|
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 5 (Week 3)
|
3.0 score on a scale
Standard Error 0.11
|
2.6 score on a scale
Standard Error 0.11
|
2.4 score on a scale
Standard Error 0.11
|
|
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 6 (Week 4)
|
3.1 score on a scale
Standard Error 0.11
|
2.5 score on a scale
Standard Error 0.11
|
2.4 score on a scale
Standard Error 0.11
|
SECONDARY outcome
Timeframe: Up to 5 weeksThe Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.
Outcome measures
| Measure |
Placebo
n=103 Participants
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Global Executive Composite T-Score
|
-7.4 T-Score
Standard Error 1.33
|
-13.6 T-Score
Standard Error 1.35
|
-14.6 T-Score
Standard Error 1.31
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Behavioral Regulation Index T-Score
|
-6.4 T-Score
Standard Error 1.15
|
-11.5 T-Score
Standard Error 1.17
|
-12.8 T-Score
Standard Error 1.14
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Metacognition Index (MI) T-Score
|
-7.2 T-Score
Standard Error 1.32
|
-13.4 T-Score
Standard Error 1.37
|
-14.2 T-Score
Standard Error 1.33
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Inhibit T-Score
|
-7.1 T-Score
Standard Error 1.22
|
-11.3 T-Score
Standard Error 1.25
|
-13.0 T-Score
Standard Error 1.21
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Self-Monitor T-Score
|
-5.2 T-Score
Standard Error 1.10
|
-10.6 T-Score
Standard Error 1.12
|
-11.9 T-Score
Standard Error 1.09
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Plan/Organize T-Score
|
-6.9 T-Score
Standard Error 1.30
|
-12.2 T-Score
Standard Error 1.33
|
-12.9 T-Score
Standard Error 1.29
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Shift T-Score
|
-4.8 T-Score
Standard Error 1.13
|
-9.8 T-Score
Standard Error 1.16
|
-10.4 T-Score
Standard Error 1.13
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Initiate T-Score
|
-5.0 T-Score
Standard Error 1.16
|
-10.3 T-Score
Standard Error 1.19
|
-11.2 T-Score
Standard Error 1.15
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Task Monitor T-Score
|
-6.8 T-Score
Standard Error 1.33
|
-12.6 T-Score
Standard Error 1.36
|
-13.5 T-Score
Standard Error 1.32
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Emotional Control T-Score
|
-3.9 T-Score
Standard Error 0.94
|
-7.1 T-Score
Standard Error 0.96
|
-8.0 T-Score
Standard Error 0.93
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Working Memory T-Score
|
-7.5 T-Score
Standard Error 1.36
|
-13.4 T-Score
Standard Error 1.40
|
-14.8 T-Score
Standard Error 1.36
|
|
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Organization of Materials T-Score
|
-4.3 T-Score
Standard Error 1.09
|
-9.5 T-Score
Standard Error 1.12
|
-10.0 T-Score
Standard Error 1.09
|
Adverse Events
Placebo
Amphetamine Sulfate (20 mg/Day)
Amphetamine Sulfate (40 mg/Day)
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo
n=106 participants at risk
Placebo, no active drug
Placebo: Matching placebo
|
Amphetamine Sulfate (20 mg/Day)
n=107 participants at risk
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
Amphetamine Sulfate (40 mg/Day)
n=107 participants at risk
Amphetamine Sulfate
Amphetamine Sulfate: active experimental AR19
|
|---|---|---|---|
|
Psychiatric disorders
Insomnia
|
3.8%
4/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
8.4%
9/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
9.3%
10/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Gastrointestinal disorders
Dry Mouth
|
3.8%
4/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
5.6%
6/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
11.2%
12/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Nervous system disorders
Headache
|
12.3%
13/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
13.1%
14/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
11.2%
12/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Infections and infestations
Nasopharyngitis
|
5.7%
6/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
4.7%
5/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
2.8%
3/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
4.7%
5/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
10.3%
11/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
13.1%
14/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Cardiac disorders
Palpitations
|
1.9%
2/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
1.9%
2/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
6.5%
7/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
5.6%
6/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
3.7%
4/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
|
Additional Information
Vice President of Clinical Development
Azurity Pharmaceuticals, Inc.
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place